Bank of New York Mellon Corp Has $63.59 Million Stock Position in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Bank of New York Mellon Corp lifted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 18,892.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 698,368 shares of the company's stock after purchasing an additional 694,691 shares during the quarter. Bank of New York Mellon Corp owned about 0.29% of BioNTech worth $63,593,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its holdings in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after purchasing an additional 246 shares during the period. Allianz SE purchased a new stake in BioNTech during the 4th quarter worth approximately $90,000. Goodman Advisory Group LLC acquired a new position in shares of BioNTech during the 1st quarter worth approximately $105,000. Tower Research Capital LLC TRC lifted its holdings in BioNTech by 61.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after acquiring an additional 713 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in BioNTech by 7.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock worth $221,000 after purchasing an additional 128 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BNTX. Morgan Stanley set a $133.00 target price on shares of BioNTech and gave the stock an "overweight" rating in a research note on Thursday, July 10th. The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective for the company. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Leerink Partners set a $112.00 price objective on shares of BioNTech in a research note on Monday, June 2nd. Finally, JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $137.91.

BioNTech Stock Performance

NASDAQ:BNTX traded down $0.35 during mid-day trading on Tuesday, reaching $110.65. 440,672 shares of the stock were exchanged, compared to its average volume of 939,967. The company has a 50 day simple moving average of $103.56 and a 200-day simple moving average of $106.76. BioNTech SE Sponsored ADR has a 1 year low of $76.53 and a 1 year high of $131.49. The stock has a market capitalization of $26.60 billion, a P/E ratio of -32.54 and a beta of 1.29. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.